- Home
- LAES vs FULC Comparison
LAES vs FULC Comparison
Compare LAES & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAES | FULC |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.2M | 718.4M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LAES | FULC |
|---|---|---|
| Price | $4.20 | $8.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 4.8M | 700.6K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $64.88 | N/A |
| Revenue Next Year | $94.93 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $2.32 |
| 52 Week High | $8.71 | $15.74 |
Technical Indicators
Market Signals| Indicator | LAES | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 36.95 |
| Support Level | $3.40 | $6.33 |
| Resistance Level | $4.43 | $9.99 |
| Average True Range (ATR) | 0.23 | 0.82 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 93.44 | 12.43 |
Price Performance
Historical ComparisonAbout LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.